Skip to main content

Pairings: Oct 26, 2011


Bernhard Sixt has resigned as CEO of Agendia, the company said this week.

Sixt, a co-founder of the company who served at its helm since 2003, will remain with Agendia in an "advisory capacity."

Agendia has tapped David Macdonald to replace Sixt as CEO. He previously served as the company's chief operating officer. Prior to that, he worked at Quest Diagnostics, Behring Diagnostics, and Novo Medical.

Macdonald holds a BS in management and finance from Northeastern University and an MBA from Babson College.

Agendia also said that Colin Goddard has joined its supervisory board of directors. Goddard is CEO of Coferon.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.